Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Juli 2023

Genmab — Juli 2023

Planlagt Fastgjort Låst Flyttet Genmab
551 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • L Offline
    L Offline
    lahn1
    wrote on sidst redigeret af
    #98

    Prøver lige igen - dejligt med stigningerne når man nåede at købe Bulls i onsdag.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      Pensionisten
      wrote on sidst redigeret af
      #99

      lahn1. synes nu, at dit indlæg 21:55 var bedst 😄

      1 Reply Last reply
      0
      • J Offline
        J Offline
        JKY_VH
        wrote on sidst redigeret af
        #100

        😄

        1 Reply Last reply
        0
        • P Offline
          P Offline
          Pensionisten
          wrote on sidst redigeret af
          #101

          Lidt lidt ærgerligt, at børsen først åbner mandag morgen 🙂

          1 Reply Last reply
          0
          • nohopeN Offline
            nohopeN Offline
            nohope
            wrote on sidst redigeret af
            #102

            Det synes jeg også. https://imgur.com/a/WXOd1T8

            1 Reply Last reply
            0
            • L Offline
              L Offline
              lahn1
              wrote on sidst redigeret af
              #103

              God morgen, det blev lidt sent igår 😄

              1 Reply Last reply
              0
              • L Offline
                L Offline
                lahn1
                wrote on sidst redigeret af
                #104

                Nohope hvad er det som giver 100+% på en dag ?

                1 Reply Last reply
                0
                • nohopeN Offline
                  nohopeN Offline
                  nohope
                  wrote on sidst redigeret af
                  #105

                  Når der er fejl på Nordnet.

                  1 Reply Last reply
                  0
                  • nohopeN Offline
                    nohopeN Offline
                    nohope
                    wrote on sidst redigeret af
                    #106

                    Ellers lækker fejl.

                    1 Reply Last reply
                    0
                    • nohopeN Offline
                      nohopeN Offline
                      nohope
                      wrote on sidst redigeret af
                      #107

                      De har desværre rettet den her til morgen.

                      1 Reply Last reply
                      0
                      • L Offline
                        L Offline
                        lahn1
                        wrote on sidst redigeret af
                        #108

                        Købte engang Bull som ikke var korrigeret ved udbytte betaling på dagen (det galt alle certifikater fra samme udbyder) . Klar fejl og tjekkede i en periode ved udbyttebetalinger på div aktier om de lavede samme fej, men desværre.

                        1 Reply Last reply
                        0
                        • P Offline
                          P Offline
                          ProinvestorNEWS
                          wrote on sidst redigeret af
                          #109

                          Johnson & Johnson Poised For A Muted Q2? https://www.proinvestor.com/investornyt/1015967/johnson-amp-johnson-poised-for-a-muted-q2

                          1 Reply Last reply
                          0
                          • P Offline
                            P Offline
                            ProinvestorNEWS
                            wrote on sidst redigeret af
                            #110

                            Antengene : Xpovio Approved In Hong Kong For Relapsed And/or Refractory Multiple Myeloma Treatment https://www.proinvestor.com/investornyt/1015963/antengene-xpovio-approved-in-hong-kong-for-relapsed-and-or-refractory-multiple-myeloma-treatment

                            1 Reply Last reply
                            0
                            • P Offline
                              P Offline
                              ProinvestorNEWS
                              wrote on sidst redigeret af
                              #111

                              Caribou Biosciences has reported new follow-up data from the dose-escalation portion of its ongoing Phase I ANTLER study, which is evaluating the allogeneic anti-CD19 CAR-T therapy CB-010 in 16 patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) https://firstwordpharma.com/story/5761039?aid=5761039

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #112

                                Both epcoritamab and talquetamab on the CHMP agenda this week https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-17-20-july-2023_en.pdf

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #113

                                  Daratumumab in first-line treatment of patients with light chain amyloidosis and Mayo stage IIIb improves treatment response and overall survival https://www.researchgate.net/publication/372343645_Daratumumab_in_first-line_treatment_of_patients_with_light_chain_amyloidosis_and_Mayo_stage_IIIb_improves_treatment_response_and_overall_survival

                                  1 Reply Last reply
                                  0
                                  • P Offline
                                    P Offline
                                    peter12
                                    wrote on sidst redigeret af
                                    #114

                                    Man kan diskutere om det er etisk korrekt at lave sådan et forsøg ?

                                    1 Reply Last reply
                                    0
                                    • E Offline
                                      E Offline
                                      E_L
                                      wrote on sidst redigeret af
                                      #115

                                      Wat do you mean Peter? The fact that the stage IIIb patients were excluded from the first trial?

                                      1 Reply Last reply
                                      0
                                      • E Offline
                                        E Offline
                                        E_L
                                        wrote on sidst redigeret af
                                        #116

                                        https://www.prnewswire.com/news-releases/treatment-with-rybrevant-amivantamab-vmjw-plus-chemotherapy-resulted-in-statistically-significant-and-clinically-meaningful-improvement-in-progression-free-survival-in-patients-with-newly-diagnosed-egfr-exon-20-insertion-mutati-301878443.html?tc=eml_cleartime Treatment with RYBREVANT® (amivantamab-vmjw) Plus Chemotherapy Resulted in Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in Patients with Newly Diagnose

                                        1 Reply Last reply
                                        0
                                        • A Offline
                                          A Offline
                                          AaBforever
                                          wrote on sidst redigeret af
                                          #117

                                          Nå...nu ser det da ud til at retningen er UP:-)

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper